Watch the On Demand video

Redefining the Treatment of Newly Diagnosed mIDH1 AML patients non-eligible for intensive therapy

25.03.2025

Now playing:

Prof Johan Maertens, MD, PhD

UZ Leuven

Background of IDH1 mutations in ND-AML

Koen Theunissen, MD, PhD

Jessa Hospital

Molecular testing and treatment outcomes in AML

Stéphane de Botton, MD, PhD

Institut de Cancérologie Gustave Roussy

Key data and practical use of ivosidenib in mIDH1 AML

Complete video

Redefining the Treatment of Newly Diagnosed mIDH1 AML patients non-eligible for intensive therapy

19:30- 19:35

Welcome and introduction by the Chair

Prof. Johan Maertens, MD, PhD - UZ Leuven, chair
19:35- 19:45

Background of IDH1 mutations in ND-AML

Prof. Johan Maertens, MD, PhD - UZ Leuven, chair
19:45- 19:55

Molecular testing and treatment outcomes in AML

Koen Theunissen, MD, PhD, Haematologist, Jessa Hospital, Hasselt
19:55- 20:20

Key data and practical use of ivosidenib in mIDH1 AML

Stéphane de Botton, MD, PhD, Haematologist, Institut de Cancérologie Gustave Roussy, Villejuif, France
20:20- 20:30

Real World Situation – Clinical Case #1

Koen Theunissen, MD, PhD, Haematologist, Jessa Hospital, Hasselt
20:30- 20:40

Real World Situation – Clinical Case #2

Stéphane de Botton, MD, PhD, Haematologist, Institut de Cancérologie Gustave Roussy, Villejuif, France
20:40- 20:55

Questions and Answers
20:55- 21:00

Summary and closure